 After a major phase III clinical trial for Alzheimer's disease (AD) treatment failed to show any benefit, three other AD trials continued.Major industry-based development in this indication essentially stopped after another Phase III trial suffered the same fate in 2012.Latrepirdine failed in the phase III trial for Huntington disease.